
|Videos|December 28, 2021
Assessing the Potential Adoption of Psychedelic Medicine in Health Care Systems
Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.
Advertisement
Pharmacy Times interviewed Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), on psychedelic medicine policy and current advancements in the field.
During the discussion, Ali addressed whether the adoption and acknowledgement of psychedelic medicine within health care systems looks likely for the future.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
AHA/ACC CKM Guideline Formally Endorses GLP-1 Therapies for Kidney, Heart Protection
2
GLP-1s and Muscle Loss: The Conversation Pharmacists Are Not Having, But Should Be
3
McKesson ideaShare 2026: Building Specialty and Infusion Capacity From the Ground Up
4
Ammoxetine: Emerging Data from a Phase 2 Antidepressant Trial
5




















































































































